← Back to patent-cliff list
Flotufolastat F-18
Tier C — Watch / tradeFlotufolastat F-18
-
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：PSMA
Brand：POSLUMA
Indications (approved)：Prostate cancer
Regional status
US
Approved
2023-05-25
EU
No progress
2020-03-02
China
Phase I
2024-09-02
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Flotufolastat F-18?
Approved indications include: Prostate cancer.
When does the Flotufolastat F-18 patent expire?
No public expiry year is available for Flotufolastat F-18 yet; this page updates once verified.
How do I get a quote for Flotufolastat F-18 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27